Recent research has turned its focus toward discovering the influence of APOE ε4 on AD biomarkers, which include amyloid‐beta (Aβ) and tau proteins in cerebrospinal fluid (CSF), as well as neuroimaging markers [4, 6]. This evidence concerns the gene MAPT and Alzheimer disease.